Alofisel
·
- Prescription status not stated
- Cancer treatments and immune-system medicines
- Active substance
- Darvadstrocel
- Made by
- Takeda Pharma A/S
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Alofisel is indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. Alofisel should be used after conditioning of fistula.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
FranceNo exact match for this strength and form
Details
| Made by | Takeda Pharma A/S |
|---|---|
| Active substance | Darvadstrocel |
| Used in | Cancer treatments and immune-system medicines |
| Classification | L04 · Cancer treatments and immune-system medicines |
| Authorised on | 2018-03-23 |
| Last updated by the regulator | 2025-04-29 |
| EMA product number | EMEA/H/C/004258 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).